AbbVie's revenue grew 10.3% year over year to $17.4B in 2026Q3, suggesting the Skyrizi and Rinvoq ramp is currently offsetting Humira biosimilar erosion at a meaningful pace.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue rose 10.3% to $17.4B in 2026Q3 and operating margin recovered to 37.3% from 12.1% a year earlier, though gross margin swings from 66% to 85% across recent quarters warrant scrutiny of cost classification and mix effects.
AbbVie is experiencing strong growth in immunology with drugs like Skyrizi and Rinvoq, which are expected to drive continued earnings growth.
Analysts hold a consensus rating of 'Buy' for AbbVie, indicating confidence in the stock's future performance.
Management has raised full-year guidance, reflecting confidence in AbbVie's future earnings potential.
AbbVie has a trailing P/E ratio that is significantly higher than the industry average, raising concerns about overvaluation.
There are worries about margin compression and a recent large one-off loss that negatively impacted net income.
AbbVie relies heavily on a concentrated group of therapies, making it vulnerable to biosimilar competition, especially as Humira sales decline.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 30, 2026 | $3.82+2.4% vs $3.73 | $17.4B+0.5% vs $17.3B |
Q3 2026 Jul 31, 2026 | $3.65+1.1% vs $3.61 | $17.0B+1.1% vs $16.8B |
Q2 2026 Apr 29, 2026 | $2.65+2.3% vs $2.59 | $15.0B+1.9% vs $14.7B |
Q1 2026 Feb 4, 2026 | $2.71+2.3% vs $2.65 | $16.6B+1.2% vs $16.4B |
Six household-name dividend payers hand you a steady paycheck, but one of them gets taxed far harder than the other five. Find out which holding belongs in a Roth first, and how the bill snowballs over two decades.
As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure with compelling growth potential.
A fat yield means nothing if the check bounces. Five payers across telecom, tobacco, pharma, real estate and pipelines show how to test coverage, and one of them carries a debt pile that could threaten its raise streak.
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Benchmark ABBV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AbbVie Inc. (ABBV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $291.31 | $514.68B | 122.92 | 8.57% | 6.91% | 6214.71% | 2.26% | |
| $276.22 | $664.92B | 25.04 | 6.05% | 16.5% | 19.86% | 1.85% | |
| $146.71 | $362.35B | 20.15 | 1.18% | 4.78% | 6.59% | 2.22% | |
| $29.39 | $167.51B | 21.61 | -1.65% | 6.34% | 4.59% | 5.85% | |
| $62.14 | $126.89B | 18.01 | -0.22% | 18.47% | 43.84% | 3.98% | |
| $1354.00 | $1.28T | 59.00 | 44.7% | 31.9% | 83.64% | 0.44% |
AbbVie Inc. (ABBV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
AbbVie Inc. (ABBV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 2, 2026·SEC
Oct 30, 2026·SEC
Oct 15, 2026·SEC
Get notified when ABBV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AbbVie Inc. (ABBV) stock FAQ — growth, dividends, profitability & financials explained
AbbVie Inc. (ABBV) reported $66.01B in revenue over the trailing twelve months. Revenue was $61.16B in fiscal year 2025. That is 291% more than the $15.64B of fiscal year 2010.
AbbVie Inc. (ABBV) grew revenue by 8.6% in fiscal year 2025, compared with the prior fiscal year.
Yes. AbbVie Inc. (ABBV) earned $10.35B in net income over the trailing twelve months (a 15.7% net margin).
Yes. AbbVie Inc. (ABBV) pays a dividend that yields 2.26% at the current price, a moderate yield.
AbbVie Inc. (ABBV) had a return on equity (ROE) of 6214.7% in fiscal year 2025. That is well above the market's typical 10-15%.
AbbVie Inc. (ABBV) generated $20.35B in free cash flow over the trailing twelve months.
